Clarivate Epidemiology’s coverage of acute musculoskeletal pain (AMP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States…
Clarivate Epidemiology’s coverage of acne comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of acne for each country, as well as…
Clarivate Epidemiology’s coverage of clostridium difficile infection (CDI) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and…
Clarivate Epidemiology’s coverage of hereditary angioedema (HAE) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of HAE for each country,…
Clarivate Epidemiology’s coverage of MRSA comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of MRSA for each country as well as…
Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
HIV is a deadly viral infection that impairs cells of the immune system and progressively destroys the body’s ability to fight infections. Availability of multiple therapeutic agents for…
Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Two high-priced JAK inhibitors (Incyte’s Jakafi and BMS’s Inrebic)…